Drug Profile
Atagabalin
Alternative Names: PD-0200390Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Hypnosedatives; Sleep disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-II for Insomnia in Canada (PO)
- 31 Mar 2009 Discontinued - Phase-II for Insomnia in USA (PO)
- 05 Apr 2008 Pharmacodynamics, pharmacokinetics, and adverse events data from a phase I trial presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008) ,,,